The quarterly dividend of $0.38 per common share will be payable
December 4, 2017, to stockholders of record at the close of business on
November 20, 2017.

About AmerisourceBergen

AmerisourceBergen provides pharmaceutical products, value-driving
services and business solutions that improve access to care. Tens of
thousands of healthcare providers, veterinary practices and livestock
producers trust us as their partner in the pharmaceutical supply chain.
Global manufacturers depend on us for services that drive commercial
success for their products. Through our daily work—and powered by our
20,000 associates—we are united in our responsibility to create
healthier futures. AmerisourceBergen is ranked #11 on the Fortune 500,
with more than $150 billion in annual revenue. The company is
headquartered in Valley Forge, Pa. and has a presence in 50+ countries.
Learn more at amerisourcebergen.com.

Certain of the statements contained in this press release are
"forward-looking statements" within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of
1934. Words such as "expect," "likely," "outlook," "forecast," "would,"
"could," "should," "can," "will," "project," "intend," "plan,"
"continue," "sustain," "synergy," "on track," "believe," "seek,"
"estimate," "anticipate," "may," "possible," "assume," variations of
such words, and similar expressions are intended to identify such
forward-looking statements. These statements are based on management's
current expectations and are subject to uncertainty and change in
circumstances. These statements are not guarantees of future performance
and are based on assumptions that could prove incorrect or could cause
actual results to vary materially from those indicated. Among the
factors that could cause actual results to differ materially from those
projected, anticipated, or implied are the following: unfavorable trends
in brand and generic pharmaceutical pricing, including in rate or
frequency of price inflation or deflation; competition and industry
consolidation of both customers and suppliers resulting in increasing
pressure to reduce prices for our products and services; changes in
pharmaceutical market growth rates; substantial defaults in payment,
material reduction in purchases by or the loss, bankruptcy or insolvency
of a major customer; changes to the customer or supplier mix; the
retention of key customer or supplier relationships under less favorable
economics or the adverse resolution of any contract or other dispute
with customers or suppliers; changes to customer or supplier payment
terms; the disruption of the Company's cash flow and ability to return
value to its stockholders in accordance with its past practices; risks
associated with the strategic, long-term relationship between Walgreens
Boots Alliance, Inc. and the Company, including with respect to the
pharmaceutical distribution agreement and/or the global sourcing
arrangement; changes in the United States healthcare and regulatory
environment, including changes that could impact prescription drug
reimbursement under Medicare and Medicaid; increasing governmental
regulations regarding the pharmaceutical supply channel and
pharmaceutical compounding; federal and state government enforcement
initiatives to detect and prevent suspicious orders of controlled
substances and the diversion of controlled substances; prosecution or
suit by federal, state and other governmental entities of alleged
violations of laws and regulations regarding controlled substances, and
any related disputes, including shareholder derivative lawsuits;
increased federal scrutiny and litigation, including qui tam litigation,
for alleged violations of laws and regulations governing the marketing,
sale, purchase and/or dispensing of pharmaceutical products or services,
and associated reserves and costs, including the reserve recorded in
connection with the proceedings with the United States Attorney’s Office
for the Eastern District of New York; material adverse resolution of
pending legal proceedings; declining reimbursement rates for
pharmaceuticals; changes in tax laws or legislative initiatives that
could adversely affect the Company's tax positions and/or the Company's
tax liabilities or adverse resolution of challenges to the Company's tax
positions; the acquisition of businesses that do not perform as
expected, or that are difficult to integrate or control, including the
integration of PharMEDium, or the inability to capture all of the
anticipated synergies related thereto; regulatory action in connection
with the production, labeling or packaging of products compounded by our
compounded sterile preparations (CSP) business; declining economic
conditions in the United States and abroad; financial market volatility
and disruption; the loss, bankruptcy or insolvency of a major supplier;
interest rate and foreign currency exchange rate fluctuations; managing
foreign expansion, including non-compliance with the U.S. Foreign
Corrupt Practices Act, anti-bribery laws and economic sanctions and
import laws and regulations; malfunction, failure or breach of
sophisticated information systems to operate as designed; risks
generally associated with data privacy regulation and the international
transfer of personal data; natural disasters or other unexpected events
that affect the Company’s operations; the impairment of goodwill or
other intangible assets, resulting in a charge to earnings; and other
economic, business, competitive, legal, tax, regulatory and/or
operational factors affecting the Company's business generally. Certain
additional factors that management believes could cause actual outcomes
and results to differ materially from those described in forward-looking
statements are set forth (i) in Item 1A (Risk Factors) in the Company’s
Annual Report on Form 10-K for the fiscal year ended September 30,
2016 and elsewhere in that report and (ii) in other reports filed by the
Company pursuant to the Securities Exchange Act.

Corporate Overview

AmerisourceBergen is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. With services ranging from drug distribution and niche premium logistics to reimbursement and pharmaceutical consulting services, AmerisourceBergen delivers innovative programs and solutions across the pharmaceutical supply channel..